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ACKGROUND: Prostate cancer (PCa) was the 
second most common type of cancer and the ifth 
leading cause of cancer-related death in men. The 
great challenge for physicians is being able to accurately 
predict PCa prognosis and treatment response in order to 
reduce PCa-speciic mortality while avoiding overtreatment 
by identifying of when to intervene, and in which patients.
CONTENT: Currently, PCa prognosis and treatment 
decision of PCa involved digital rectal examination, 
Prostate-Speciic Antigens (PSA), and subsequent biopsies 
for histopathological staging, known as Gleason score. 
However, each procedure has its shortcomings. Efforts 
to ind a better clinically meaningful and non-invasive 
biomarkers still developed involving proteins, circulating 
tumor cells, nucleic acids, and the ‘omics’ approaches.
SUMMARY: Biomarkers for PCa will most likely be an 
assay employing multiple biomarkers in combination using 
protein and gene microarrays, containing markers that are 
differentially expressed in PCa.
KEYWORDS: prostate cancer, PSA, biomarkers, 
nomograms, miRNA, proteomic, genomic, metabolomic
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ATAR BELAKANG: Kanker prostat / prostate 
cancer (PCa) merupakan kanker kedua yang 
paling sering ditemukan, dan menduduki urutan 
kelima sebagai penyebab kematian pada pria. Tantangan 
terbesar bagi para dokter adalah bagaimana dapat 
memprediksi dengan akurat prognosis dan respon terapi 
PCa dengan tujuan untuk mengurangi kematian akibat PCa, 
tanpa memberikan terapi yang berlebihan, serta mampu 
mengidentiikasi waktu intervensi yang tepat pada pasien 
yang tepat.
ISI: Saat ini, prognosis dan terapi PCa dilakukan atas 
dasar pemeriksaan rektal digital, Prostate-Speciic 
Antigens (PSA), dan biopsi untuk mengetahui derajat 
histopatologisnya, yang dikenal sebagai skor Gleason.
Bagaimanapun, setiap prosedur memiliki keterbatasannya. 
Usaha untuk menemukan biomarker yang bermanfaat secara 
klinis dan tidak invasif masih terus dilakukan menggunakan 
protein, sel tumor di sirkulasi, asam nukleat, dan pendekatan 
“omics”.
RINGKASAN: Biomarker PCa akan berupa suatu 
kombinasi biomarker, meliputi protein dan microarray gen 
yang berisi banyak marker yang diekspresikan pada PCa.
KATA KUNCI: kanker prostat, PSA, biomarker, 
nomogram, miRNA, proteomic, genomic, metabolomic
Abstract Abstrak
Introduction
Prostate cancer (PCa), also known as carcinoma of the 
prostate, is the development of cancer in the prostate, a 
gland in the male reproductive system. Globally, PCa was 
the second most common type of cancer and the ifth leading 
cause of cancer-related death in men. It was estimated 
about 233,000 new cases and 29,480 deaths from PCa in 
the United States in 2014, and 9,033 annual incidences with 
ͳʹͶ
The Indonesian Biomedical Journal, Vol.6, No.3, December 2014, p.123-36 Print ISSN: 2085-3297, Online ISSN: 2355-9179
would then increase the likelihood of a cell developing 
ensuing mutations (‘multiple hits’) that allow PCa cell to 
grow independently of androgen (androgen-independent 
PCa) (AIPC). There are many proposed mechanisms how 
the PCa can develop into AIPC (see Table 1).
 The primary causes and the molecular mechanisms 
underlying of PCa are poorly understood. This is the reason 
why there are no effective prevention strategies or treatment 
modalities to cure advanced PCa. Several aspects suggested 
involved in PCa development including: [1] higher oxidants 
and electrophiles exposure, both exogenous (environmental 
toxins and dietary) and endogenous (cellular metabolism, 
mitochondrial dysfunction, hypoxia) in individual with PCa. 
It was well-known that oxygen radicals can directly attack 
DNA, promoting chronic oxidative stress which results in 
lipid peroxidation and generation of wide range of other 
reactive products with the potential to damage DNA (18,19), 
[2] Phagocytic inlammatory cells release reactive oxygen 
and nitrogen species in attempts to eradicate infectious 
organisms (or perceived infectious organisms). Repeated 
bouts of this immune-mediated oxidant and nitrogenous 
injury over many years developed chronic inlammation 
and could play a major role in the pathogenesis of cancer 
(20). [3] Focal prostatic gland atrophy occurs primarily in 
Pathophysiology of PCa
6,841 mortality cases in Indonesia until year 2008.(1,2,3)
 PCa is very uncommon in men younger than 45, but 
becomes more common with advancing age. The average 
age at the time of diagnosis is 70.(4) However, many men 
never know they have PCa, this was because early PCa 
usually causes no symptoms, or often have symptoms 
similar to any prostatic diseases such as benign prostatic 
hyperplasia, or prostatitis. These include frequent urination, 
nocturia (increased urination at night), dificulty starting 
and maintaining a steady stream of urine, hematuria (blood 
in the urine), and dysuria (painful urination).(5,6)
 The great challenge for physicians is being able to 
accurately predict PCa prognosis and treatment response 
in order to reduce PCa-speciic mortality while avoiding 
overtreatment by identifying of when to intervene, and 
in which patients.(7) Although risk stratiication using 
Prostate-Speciic Antigens (PSA), Gleason grading and T 
stage have helped tremendously in determining if active 
surveillance is an appropriate option and in deining the 
optimal treatment for localized PCa (8), recent data suggest 
that many men with localized PCa, even of higher grade, do 
not enjoy a survival beneit from treatment (9). Thus, a large 
number of men are subjected to toxicities of treatment such 
as radiation or surgery with resulting decrement in quality 
of life with no potential beneit. The ability to predict with 
biomarkers which local therapy could provide the best 
chance of disease control and the patients susceptibility 
to toxicities of certain treatments would provide another 
chance to improve disease control outcomes and predict for 
toxicity from radiation.(10,11)
Prostate is a part of the male reproductive system that helps 
make and store seminal luid, about 3 centimeters long and 
weighs about 20 grams in adult men contains many small 
glands which make about 20 percent of the luid constituting 
semen. The prostate located in the pelvis, under the urinary 
bladder and in front of the rectum. It surrounds part of the 
urethra, the tube that carries urine from the bladder during 
urination and semen during ejaculation. That’s why prostate 
diseases often affect urination, ejaculation, and rarely 
defecation.(12-14)
 PCa happened when the cells of these prostate glands 
mutate into cancer cells. The growth of PCa depends on 
the ratio of cells proliferating to those dying. Androgen are 
the main regulator of this ratio between cell proliferation 
stimulating and apoptosis. This called androgen-dependent 
PCa (16). Somehow, a general increase in the mutation rate 
Figure 1.  Anatomy of prostate. (15) (Adapted with permission 
from Wikipedia).
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Table 1. Mechanisms of development of AIPC.(17) (adapted with permission from Nature Publishing Group).
the outer part of the gland, referred to as the peripheral zone, 
the preferred site for carcinoma, because most focal prostate 
lessions appear to be proliferative rather than quiescent. The 
proliferation is increased, while apoptosis is not (21-23). [4] 
The telomere shortening contribute in genetic instability and 
develop PCa (24). These understanding of PCa developing 
mechanisms was expected to be the foundation for researcher 
and clinicians to ind better biomarkers for diagnosing PCa 
in early stage, can accurately predict and monitor the tumor 
progression, and the response to treatments.
Accurate and timely assessment of PCa prognosis remains 
as one of the most challenges in PCa management. Rapid 
advances in molecular technology, and overwhelming 
number of proposed biomarkers nowadays still can not 
prevent many over-diagnosed of PCa and many patients 
are treated in an unnecessarily aggressive manner. Possible 
reasons are the complex nature of this disease.(25) 
Currently, PCa prognosis and treatment decision involved 
digital rectal examination,  PSA, and subsequent biopsies 
for histopathological staging, known as Gleason score.(26) 
However, each procedure has its shortcomings, and here, we 
will summarize some promising biomarkers for PCa.
 A biomarker is a measurable biological indicator that 
can provide information about the presence or progression 
of a disease or the effects of a given treatment. A clinically 
useful biomarker should be safely obtainable from the 
Identification of Biomarkers for PCa
patient by non-invasive means, have high sensitivity and 
speciicity, high positive and negative predictive values, 
and facilitate clinical decisions that allow optimal care to be 
administered.(27) 
PSA
PSA or human kallikrein-related peptidase 3 (hKLK3) is a 
33 kDa glycoprotein of the kallikrein family, encoded by 
the hKLK3 gene located in the long arm of chromosome 
19 within the region spanning q13.2–q13.4. In normal 
prostate, PSA is secreted from the prostatic epithelium into 
the secretory ducts to contribute to the seminal luid. In PCa, 
disruption of the basal-cell layer allows PSA to “leak” into 
the circulation resulting in elevated serum levels of PSA. 
Therefore, it is organ speciic and not disease speciic.(28-
30) PSA also can be elevated in other benign conditions of 
the prostate. This makes PSA not speciic to PCa though 
it has been regarded as the best cancer biomarker due to 
its high sensitivity.(31) This high false - positive rates 
increasing the risk of patients’ overdiagnosed and having 
unnecessary treatment or surgery, while insigniicantly 
decreasing the mortality due to PCa.(32) Positive predictive 
values for PSA have shown it to operate at 37%, with 25% 
of men in the ‘gray zone’ (4–10 ng/ml) having PCa (33) 
and 15% of individuals with PSA concentrations ≤4 ng/ml 
having PCa (34).
 To increase its accuracy, several methods of measuring 
PSA have been developed that include: monitoring personal 
PSA changes over time (PSA velocity); the ratio of PSA to 
prostate volume (PSA density) determined by transrectal 
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ultrasound; and PSA ranges that are speciic to age, measuring 
the splice isoforms and complexed forms of PSA (free PSA 
(fPSA) versus total PSA (tPSA)) which shown to have a 
predictive value for late-stage PCa, and help discriminate 
between PCa and Benign Prostatic Hypertrophy (BPH) 
for men with “gray zone” PSA.(35,36) PSA in circulation 
has also been found to be complexed to other binding 
proteins and this measurement has shown to add clinical 
utility. These include PSA bound to a2-macroglobulin, a1-
antichymotrypsin and a1-protease inhibitor. In addition, 
there are several post-translationally modiied cleavage 
isoforms of PSA that have been measured speciically.(37)
Gleason Score
Currently, Gleason grading is considered to be the best 
predictor of outcome. The Gleason score is a number 
derived from the biopsy specimen a pathologist sees under a 
microscope, based on the degree of loss of normal glandular 
tissue.(38) Pathologist will look for the most prominent cell 
type, (the primary Gleason grade), then the second most 
prominent cell type (the secondary Gleason grade). The 
numerical grade range from 1 to 5. The sum of the primary 
grade plus the secondary grade equals the Gleason score. 
Patients with Gleason scores 7 or higher are at increased 
risk of extraprostatic extension and recurrence after therapy.
(8,39).
 The multifocal nature of PCa, whereby different 
genetic alterations may exist in different tumor foci of a 
prostate, however, increases the likelihood of missing a 
high-grade focus. Furthermore, the risks associated with 
biopsies, such as bleeding and increased risk of infections 
potentially leading to sepsis, underscore the need for 
alternative approaches for accurate prognosis.(40)
hKLK2
hKLK2 is a serine protease enzyme from the kallikrein 
family of serine proteases, the same gene family as PSA, 
and shows 80% sequence homology with PSA, although 
its enzymatic activities differ.(41,42) Tissue expression of 
KLK2 has been shown to correlate well with PCa progression 
and tumor volume and has been studied as a peripheral 
marker in serum in combination with PSA and fPSA.(43-
45) KLK2 has also been shown to have independent clinical 
utility as a prognostic indicator for biochemical recurrence 
in men with PSA ≤10 ng/ml.(46)
Prostate Cancer Antigen 3 (PCA3)
PCA3, also known as Differential Display Code 3 (DD3), is 
a noncoding RNA that speciically expressed in the prostate 
and highly expressed in over 90% of PCa tumors compared 
with BPH specimens.(47-49) PCA3 can be detected in 
urine and prostatic luid.(50) A ratio of the PCA3:PSA 
RNA, known as the PCA3 score, is used, in combination 
with other clinical information, to guide decisions on repeat 
biopsy in men who are 50 years of age or older and who 
have previously had at least one negative prostate biopsy 
(PBX).(51)
Nomograms for Predicting PCa
According to current European Association of Urology 
(EAU) guidelines, the need for PBX should be further 
determined on consideration of patient’s biological 
age, potential comorbidities (American Society of 
Anesthesiologists [ASA] Index and Charlson Comorbidity 
Index), and the therapeutic consequences (risk stratiication), 
to prevent a signiicant proportion of men from being 
exposed to unnecessary procedures and associated 
psychological distress.(52)
 To improve prediction of PBX outcome and better 
counsel patients either to undergo or forgo PBX, statistical 
models have been developed that combine the strengths 
of several clinical variables. There are different forms 
of prediction models, for example, nomograms or risk 
calculators. Risk calculators are based on logistic regression, 
resulting in a risk score to support clinical decision-making 
for PBX.(53-55) Ideally, a nomogram should be capable of 
identifying PCa at PBX without missing men with high-
grade PCa, and preventing a signiicant proportion of men 
without, or with insigniicant, PCa from undergoing PBX. 
The intention is to reduce disease morbidity and mortality by 
detecting signiicant PCa at an early stage, and at the same 
time to avoid overdiagnosis as well as overintervention.(56)
 Nomogram prediction can never be perfect, which 
is shared with all prognostic models and is mainly due to 
lack of consideration of all predictive risk factors and the 
inability to assemble all known prognostic factors optimally.
(57) Some tests that may have the potential to hold up to 
their promise when it comes to prediction of PCa risk are the 
Prostate Health Index (PHI), PCA3 and a human kallikrein 
panel.(56) 
 The PHI is a new formula that combines all three 
PSA isoforms (tPSA, fPSA and [-2]proPSA or p2PSA) into 
a single score that can be used to aid in clinical decision-
making.(58) PHI is calculated using the following formula: 
(p2PSA/fPSA) × √PSA. Intuitively, this formula makes 
sense, men with a higher tPSA and p2PSA with a lower 
fPSA are more likely to have clinically signiicant PCa.(59) 
Combined serum hKLK2 to three other kallikreins (tPSA, 
fPSA and intact PSA) called as the ‘four kallikrein panel’ 
demonstrated improved predictive accuracy of PBX outcome 
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in men with elevated tPSA levels. Predictive accuracy 
increased from 72 to 84% in an external validation cohort, 
leading to a reduction of unnecessary biopsies (60). Only 
four urinary PCA3-based nomograms have been previously 
published, mostly combining patients’ age, Digital Rectal 
Examination (DRE), PSA, fPSA, sampling density and PCA-
3. Two are proposed to all patients, whatever the medical 
history of previous biopsies, and were externally validated: 
the updated version of the PCa Prevention Trial (PCPT) 
risk calculator  and the graphically available nomogram 
published by Chun et al.(61-63) Another is speciically 
dedicated to patients scheduled for repeat biopsy (64), while 
the last one, very recently published by Hansen et al. (65), 
has been developed for guiding the initial biopsy decision. 
Both Hansen’s and Chun’s nomograms proved to provide 
signiicant clinical beneit without missing a too important 
proportion of high-grade PCa (HGPCa).(62,65)
Homeobox-containing Transcription Factor Engrailed-2 
(EN2)
The Homeobox gene family incorporates over 100 members, 
which each encode a homeo-domain-containing protein, 
this domain itself being a 61 amino acid protein. This 
speciic domain acts as a binding site for other proteins to 
enable activation or repression of downstream target genes. 
EN2 is a homeobox-containing transcription factor secreted 
speciically by PCA into urine, where it can be detected by 
a simple ELISA assay.(66)
 EN2 was originally identiied as a potential oncogene in 
breast cancer, as forced overexpression of the gene promoted 
malignant characteristics in mammary cell lines (67), but 
then hypermethylation of EN2 has also been identiied in 
several cancers, including lung and astrocytoma, although 
its speciic role is yet to be characterized.(68,69) EN2 
protein expression irst conirmed in PCa tissue (and the 
absence of EN2 in normal prostate or non-cancer prostatic 
disorders) in 2011.(70)  Secretion and deposition of EN2 
protein into urine by men with PCa was hypothesized and 
subsequently conirmed by western blot analysis of urinary 
supernatant. An ELISA test has been developed for the 
accurate quantitation of urinary EN2, and a point of  care 
test has been developed and is being evaluated.(70)
 Many studies showed the potential utility of urinary 
EN2 not only as a diagnostic biomarker for PCa, but also as 
an accurate indicator of PCa volume. Noninvasive measures 
of cancer volume will be extremely useful in aiding the 
urologist to offer radical treatment versus advising an 
active surveillance approach. The EN2 test is a robust, 
simple, low-cost urine-based test. EN2 protein in urine 
is stable for at least 4 days at room temperature allowing 
patients samples to be collected and transported routinely 
at low cost. However, there are a number of remaining 
unresolved issues. These include the need to understand 
the EN2 expression regulation and secretion by cancer 
cells, determining whether the cut-off level of 42 ng/ml is 
optimal, the correlation of EN2 with tumor grade, deining 
the role of EN2 in monitoring patients after radiotherapy or 
hormonal therapy and, probably most immediately, whether 
EN2 secretion in some way can be used in conjunction with 
serum PSA to improve diagnostic eficacy (71). 
ETS-related Gene (ERG)
Transmembrane protease, serine 2 (TMPRSS2) and E26 
transformation-speciic (ETS) transcription factors fusions 
in PCa were initially discovered by cancer proile outlier 
analysis to be present in 80% of prostate tumors studied.(43) 
Since this initial discovery, many other similar gene fusions 
have been discovered associated to PCa.(72) Tomlins et al. 
(73) irst reported the occurrence of a recurrent TMPRSS2-
ERG fusion transcript in those with prostate tumors. These 
fusions were detectable in 42% of urinary expressed 
prostatic secretion samples from men with prostate cancer, 
and less in prostatic intraepithelial neoplasia (PIN) and BPH 
tissues (74). Another area in which the clinical utility of the 
cancer-speciic TMPRSS2–ERG fusion product is currently 
being extensively investigated is urine-based detection 
in a preoperative setting for early diagnosis of PCa and, 
potentially, to distinguish indolent versus aggressive disease 
(75-78). The urine assay measures TMPRSS2–ERG mRNA 
relative to PSA mRNA (TMPRSS2–ERG score) in post-
digital rectal exam urine.(75,76)
 Two important limitations of ERG was critical to be 
aware are: irst, the intertumoral (between different cancer 
foci) heterogeneity of ERG expression might limit its use 
in a preoperative (biopsy) setting; second, the molecular 
heterogeneity of PCa arising from different zones of the 
gland impacts on the prevalence of ERG rearrangement 
status. Then, the combination of TMPRSS2-ERG score 
with another multiple urine biomarker may increase the 
diagnostic and prognostic value of single assays and may 
reduce the number of prostate biopsies performed in the 
future.(79)
Urinary Biomarkers: α-Hepatocyte Growth Factor 
(αHGF), Insulin-like growth factor-binding protein 3 
(IGFBP3), and Osteopontin (OPN)
Protein urinary markers have more potential for functionally 
interrogating the tumor, as prostatic products are directly 
secreted into the urinary tract, theoretically increasing the 
possibility of detection developed by ELISA, and do not 
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require exfoliated cancer cells to be present for detection. A 
combination of markers may provide improved diagnostic 
and prognostic accuracy, thus alleviating unnecessary 
procedures, cost and morbidity.(80)
 Three speciic proteins as biomarkers for PCa are: 
αHGF, IGFBP3 and OPN. These proteins have yet to be 
identiied as urinary biomarkers in PCa, but have been 
shown to play key roles in PCa initiation and progression. 
HGF is a pleiotropic cytokine that has been implicated in 
angiogenesis, adhesion, migration, invasion and proliferation 
of PCa cells.(81) Elevated quantities of activated HGF have 
been detected in serum of PCa patients.(82) Similarly, 
elevated levels of c-Met, the tyrosine kinase receptor for 
Figure 2. (a) PCA3 nomogram predicting 
cancer on prostate biopsy; (b) local 
regression nonparametric smoothing 
plots showing the calibration of the 
PCA3 nomogram; (c) local regression 
nonparametric smoothing plots showing 
the calibration of the base nomogram. 
Instructions for physicians: To obtain 
nomogram-predicted probability of 
prostate cancer, locate patient values 
at each axis. Draw a vertical line to the 
‘‘Point’’ axis to determine how many 
points are attributed for each variable 
value. Sum the points for all variables. 
Locate the sum on the ‘‘Total Points’’ 
line to be able to assess the individual 
probability of cancer on prostate biopsy 
on the ‘‘Probability of prostate cancer 
at biopsy’’ line. Instructions for readers: 
Perfect predictions correspond to the 
458 line. Points estimated below the 458 line correspond to 
nomogram overprediction, whereas points situated above the 458 
line correspond to nomogram underprediction. A nonparametric, 
smoothed curve indicates the relationship between predicted 
probability and observed frequency of prostate cancer on initial 
biopsy. Vertical lines indicate the frequency distribution of predicted 
probabilities.(62) (Adapted with permission from Elsevier).
HGF, have been detected in the urine of PCa patients. 
(83,84) Current inding shown a signiicant overexpression 
of αHGF in PCa urine samples as compared with controls, 
supported by evidence of similar indings in serum and 
plasma HGF biomarker studies.(83,85) In particular, the 
mechanism of elevating αHGF can be associated with 
the pathway involving its receptor, c-met, and proteolytic 
enzymes, HGFA and matriptase, which cleave HGF to form 
a biologically active heterodimer.(82) This suggests that 
aHGF levels increase to initiate the cancer phenotype, but 
αHGF cannot discriminate between localized and metastatic 
disease.(86)
 IGFBP3, a component of the IGF system, has been 
reported to be involved with cellular differentiation, survival 
and proliferation; recent studies have shown higher levels 
of plasma IGFBP3 to correlate with an increased likelihood 
of harboring PCa.(87) Urinary αHGF and IGFBP3 can be 
used to differentiate between individuals with and without 
cancer, while OPN levels can be used to identify those with 
more aggressive disease.
 OPN, also known as secreted phosphoprotein 1 (SPP1), 
is an extracellular matrix protein with a number of diverse 
roles, including blood vessel formation and tumorigenesis.
(88) OPN has been found to have signiicantly increased 
expression at the mRNA and protein levels in patients 
with aggressive PCa.(89) Thalmann et al. found levels of 
urinary OPN to be signiicantly higher in metastatic samples 
compared with localized disease and normal samples, 
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such, a surrogate marker of angiogenesis. CEP irst isolated 
in peripheral blood by Asahara and colleagues in 1997.(101) 
Unlike CECs, CEPs are mobilized from bone marrow (BM). 
A population of CEPs have clonogenic and proliferative 
potential (endothelial colony  forming cell).(102) CEPs are 
relatively rare in healthy individuals. Within the vessel wall, 
BM -derived CEPs are thought to merge and differentiate 
into endothelial cells.(103)
 Many factors contribute to the conlicting body of 
evidence regarding CEC and CEP levels as biomarkers in 
cancer. Among these, the most signiicant is the differences 
in enumeration methodology. No one marker can uniquely 
identify CECs and CEPs, and there is no agreement on 
which combination of markers can identify them reliably, 
although it is reasonable to hypothesize that these cells 
have the potential to be valuable biomarkers, given the 
importance of angiogenesis in cancer. The lack of research 
in this area probably relects the methodological challenges 
of enumeration of these cells rather than a lack of scientiic 
interest.(104)
 Platelets play a number of signiicant roles in metastatic 
disease.(105-107) One role is the facilitation of certain 
steps of hematogenous metastasis.(108) Platelets actively 
signal to tumor cells via the transforming growth factor β 
(TGFβ) and nuclear factor kB (NF kB) pathways. Inhibition 
of these pathways protects against lung metastasis in vivo.
(109) Metastasis can be signiicantly reduced through 
depletion of platelets or inhibition of tumor cell induced 
platelet aggregation.(107) Platelets are also able to protect 
tumor cells from attack by the immune system, by limiting 
the ability of natural killer cells to lyze tumor cells in vitro 
and in vivo.(107) Further investigation showed there was 
no difference in total platelet count between patients who 
did and did not recur (110), but a subset of platelets showed 
signiicantly correlated with early biochemical recurrence 
in PCa after prostatectomy. Although platelets have a well 
established role in cancer, some large investigation in 
exploratory studies and further evaluation in prospective 
trials should be established before recommendations can be 
made regarding their use in routine PCa care.(104).
Circulating Tumor Cells (CTCs)
As a tumor progresses, it sheds its cells into the bloodstream 
and these cells may form distant metastases. Detecting 
and measuring CTCs by isolating them and performing 
reverse transcriptase polymerase chain reaction (PCR) of 
PCa - speciic genes has shown promise in the diagnosis 
and prognosis of PCa. Changes in CTC levels may be more 
accurate than PSA in predicting outcomes for castration-
resistant prostate cancer (CRPC).(111) Patients with 
which conirm previous indings that have linked OPN to a 
malignant phenotype.(90)
Tumor Vascularity in PCa
Tumors require an increased blood supply for growth. 
Inducing angiogenesis is one of the hallmarks of cancer (91) 
and a critical mechanism behind tumor dormancy (92). The 
transition from dormancy to outgrowing vascularized tumor 
occurs when the balance tips in favor of angiogenesis. This 
is referred to as the ‘angiogenic switch’ and is controlled 
by both anti-angiogenic and pro-angiogenic regulators 
(93). Neovasculature can arise from the sprouting of new 
vessels from existing ones (angiogenesis), or de novo vessel 
formation from circulating endothelial precursor cells 
(vasculogenesis).(91) Tumor vessels are characteristically 
heterogeneous, in contrast to normal mature blood vessels.
(94)
 Tumor vascularity in PCa has been linked to disease 
aggressiveness, where highly vascularized tumors are more 
responsive.(95)  Microvessel density (MVD) has been used 
as a histological marker of cancer vasculature. MVD can 
be calculated using analysis of vascular ‘hot spots’, random 
area selection, larger representative areas of the specimen 
or even whole specimen analysis, and automated analysis 
was used to reduce bias.(96-98) Aggressive prostate tumors 
are seen to form vessels primitive in morphology and 
function. Poorly differentiated tumors have greater MVD, 
irregularity of vessel lumen and smaller vessels. In addition, 
tumors exhibiting the smallest vessel diameter or the most 
irregularly shaped vessels have been associated with the 
development of lethal disease.(99) However, MVD is not 
consistent across all studies.(96) By contrast, transition 
zone tumors display a large variability in microvascular 
parameters. They can be both hypo - or hyper- vascularized 
compared with normal transition zone tissue.(98) MVD 
failed to provide an independent prognostic factor when 
combined with standard predictors in a multivariable 
analysis.(100) Therefore, MVD has a limited application in 
the clinical setting.
 Circulating endothelial cells (CECs) and circulating 
endothelial progenitors (CEPs) comprise subsets of cells 
that are different functionally and phenotypically. Both 
relect angiogenesis and have been heralded as promising 
noninvasive biomarkers for the prediction of prognosis 
and evaluation of treatment response in cancer. CECs are 
mature, terminally differentiated cells that are shed from the 
vessel wall into the circulation in response to injury or as a 
result of endothelial dysfunction. However, the precise role 
of CECs in malignancy is unclear. At this stage, CECs are 
best understood as a product of vascular turnover and, as 
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a CTC count of more than 5 CTCs/7.5 mL blood have a 
signiicantly reduced overall survival compared to patients 
with less than 5 CTCs/7.5 mL blood. (112,113) PCa CTCs 
are reported to relect those mutations present in the primary 
tumor e.g., TMPRSS2-ERG fusions, androgen receptor 
mutations, and Phosphatase and Tensin Homolog (PTEN) 
deletion which, together with PSA, alpha-methylacyl-CoA 
racemase (AMACR) and androgen receptors, can predict 
the response to treatment.(114,115) The number of CTCs 
present in whole blood might allow for determination of 
cancer burden, and provide a more readily accessible source 
of molecular information of the primary tumor. Despite their 
promise and proposed function, CTC detection remains a 
major technical challenge (116) and their clinical relevance 
remains controversial. In addition, the labor-intensive nature 
of isolating CTCs, high cost and the extremely low numbers 
in blood is a technical hurdle, especially in the early stages 
of PCa.(117)
TGFβ-1
TGF-β1 is a ubiquitous growth factor that has been 
implicated in several molecular processes relating to cell 
proliferation and differentiation, cytokine response during 
inlammation and new blood vessel growth. TGF-β1 has 
been shown to be overexpressed in PCa tissue specimens 
and correlates with tumor grade and metastasis.(118) 
TGF-β1 also correlate with prostate tumor extravasation 
and biochemical recurrence.(119) Furthermore, circulating 
TGF-β1 has been shown to be elevated in PCa patients.
(120) In combination with other markers, TGF-β1 could 
prove to have clinical utility for PCa prognosis.
Autoantibodies in PCa
Cancers are known to activate the cellular immune system, 
including the mounting of an autoimmune response 
to antigens presented by the tumor.(121) Detection of 
autoantibodies produced against AMACR in PCa patients 
in the gray zone of 4–10 ng/ml were shown to stratify PCa 
from non-PCa with a sensitivity of 62% and speciicity of 
72%.(122)
AMACR
Immunohistological markers of PCa are also important in 
distinguishing between prostate tumor stages during biopsy 
analysis. AMACR is an enzyme involved in the synthesis 
and metabolism of fatty acids and has been shown to have 
high expression in prostate tissues, about 80-100% in 
PCa tissues (123), detected in blood and urine with a high 
sensitivity and speciicity (122,124,125). AMACR also 
correlates with PCa metastasis and biochemical recurrence 
when levels are lowered, and its inhibitors have potential to 
provide a novel treatment for CRPC. However, AMACR is 
also expressed in many other tissues, thus limiting its utility 
as a tissue marker for PCa.(124)
Cell-free circulating DNA or mRNA are attractive to 
clinicians and scientists because of their potential for 
minimally invasive detection and monitoring of disease 
pathogenesis, but some technical challenges in terms of 
sensitivity, speciicity and/or nucleic acid stability are still 
in considerate currently. In contrast to mRNA, circulating 
DNA-based tumor markers exhibit greater stability 
and enhanced tumor speciicity, potentially enabling 
tumor grading/staging, prognostic estimation and aiding 
therapeutic decision-making.(126) In prostate cancer, three 
types of DNA alterations have been investigated as plasma/
serum biomarkers. These are mitochondrial DNA (mtDNA) 
mutations (127-130), microsatellite instability (MI) (131-
135), and gene promoter hypermethylation (132,135-145).
Hypermethylation Event
Hypermethylation of CpG islands within the promoter of the 
gene encoding GSTP1, a tumor-suppressor protein involved 
in detoxiication processes, has been described as one of 
the earliest events in prostate carcinogenesis and leads to 
loss of gene expression.(126) Measurements in urine after 
prostatic massage have shown that decreased expression of 
GSTP1 mRNA correlates with positive biopsies.(146,147) 
In addition, the promoter methylation status of GSTP1 in 
urine has been measured and shown to have speciicities 
of 93–100% for PCa detection and sensitivities of 21.4–
38.9%.(148-151) However, it was shown in other studies 
that after prostatic massage the sensitivity increased to 75%.
(152,153)
MI
Microsatellites are repeated sequences of DNA made of 
repeating units of 1-6 base pairs in length. Microsatellite 
stretches may be disrupted by base substitutions (imperfect 
microsatellites) or insertions (interrupted microsatellite). 
MSI structure consists of repeated nucleotides, most often 
seen as GT/CA repeats. A higher number of repeats causes a 
higher mutation rates (154).
 Increased frequency of MI markers was identiied in 
patients with metastatic prostate cancer.(131) Introduction 
of additional markers of MI or gene methylation may be 
Circulating Nucleic Acid as 
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required to increase sensitivity of prostate cancer detection 
and overcome the high degree of tumor heterogeneity that 
is often observed in prostate cancer, and to accommodate 
differences in clearance rates of circulating tumor-associated 
DNA.(126)
mtDNA
Jeronimo et al. sequenced the D-loop region, 16S ribosome 
RNA (rRNA) and complex I of mtDNA in primary prostate 
tumors and in patients’ urine and plasma, to investigate 
whether mtDNA is mutated in prostate cancer. Twenty 
mtDNA mutations were described in primary tumors, and 
where mtDNA mutations were identiied in plasma, these 
were also found in primary tumors of affected patients. 
However, such mutations were a relatively rare event, 
with mtDNA mutations identiied in only three of 16 
patients examined, limiting the diagnostic potential of such 
mutations.(128)
 mtDNA appears to be of greater prognostic than 
diagnostic utility in prostate cancer serum/plasma, 
particularly in advanced prostate cancer, where patients 
who did not survive to 2-year follow-up had 2.6-fold 
higher circulating mtDNA level at initial presentation than 
surviving patients.(129)
Circulating mRNA
The utility of circulating mRNAs as biomarkers is hampered 
by the low speciicity of quantitative PCR (qPCR)-based 
assays, and use of target mRNAs that are prostate-speciic, 
but not always prostate cancer-speciic. Circulating mRNA 
is less stable than circulating DNA, resulting in lower 
abundance of mRNA targets for qPCR applications. Thus, 
circulating mRNAs have demonstrated potential for dis- 
tinguishing patients with organ-conined disease from those 
with metastatic disease (126).
 BMP6 expression has been demonstrated to be high in 
primary tumors of patients with metastatic prostate cancer 
and low or undetectable in individuals with localized, 
nonmetastatic prostate cancer and in benign prostate 
tissue, and appears to play a key role in promotion of bone 
metastasis by enhancing osteoblastic and invasive PCa 
abilities of prostate cancer cells. Plasma BMP6 mRNA 
levels, in combination with PSA, can be used as an indicator 
of disease progression and/or treatment response.(155,156)
 The lengths of the telomeric ends of chromosomes 
are maintained by the enzyme human telomerase reverse 
transcriptas (hTERT). Overactivity of hTERT has been 
shown to be present in 90% of PCa tissues.(157) Patients 
with high levels of plasma hTERT mRNA demonstrated 
reduced recurrence-free survival compared with those with 
low levels, an effect not observed for plasma PSA.(158) 
AGR2 mRNA may also have a role as a potential biomarker 
for prostate cancer. The protein product of this gene is 
associated with metastatic progression and cell migration in 
prostate cancer cells, and urine anterior gradient 2 (AGR2) 
levels have been investigated as a putative diagnostic 
prostate cancer biomarker.(159,160) AGR2 mRNA levels 
are signiicantly elevated in patients with metastatic prostate 
cancer, and are highest in patients with clinicopathological 
indicators of NP-CRPC (161). AGR2 mRNA levels may be 
used as an aid to noninvasively identify patients with NP-
CRPC and to subsequently assist with treatment planning 
(161).
Circulating micro RNA (miRNA)
miRNAs are naturally occurring single-stranded RNA 
molecules, 19-25 nucleotides in length, PCa able of post-
transcriptional regulation of target mRNAs to which they 
bind, at complementary sequences most frequently in the 
3'-untranslated region. Reduced levels of the encoded 
protein result from subsequent translational repression or 
mRNA degradation. Furthermore, miRNAs can function 
as either oncogenes, encouraging tumor growth, or tumor 
suppressors, repressing it collectively termed oncomirs.
(162) The desirable properties of miRNAs in the context 
of circulating biomarkers include stability (they are stable 
even in archival samples) and availability (they have been 
isolated from most body luids).(163) Tumor cells release 
miRNAs into the blood and circulating expression proiles 
of miRNAs are altered in many tumor types, suggesting 
that miRNA proile can be informative about the disease.
(164,165) Furthermore, detection and quantitation can be 
relatively easily achieved in low volumes of blood serum or 
plasma qPCR, which is both speciic and sensitive.(166) PCa 
associated miRNAs in serum allow for minimally invasive 
diagnostic separation of samples from tumor burdened and 
healthy patients. miR-21, miR-125b, miR-221 and miR-222 
are part of the oncogenic miRNA family that are upregulated 
in human aggressive PCa.(167) miR-21 is overexpressed 
in PCa and other tumors acting as an oncogenic regulator 
leading to tumor growth (168) by silencing PTEN and 
other tumor suppressing genes.(169) The miR-200 family 
has recently generated interest in PCa research due to their 
lowered expression in PCa. A study of a Chinese population 
(140) identiied a panel of ive miRNA markers (let7-c, 
let7e, miR-30c, miR-622 and miR-1285) that differentiated 
PCa from benign and healthy control samples. However, 
for a larger clinical utility, these circulating nucleic acid 
biomarkers require extensive and detailed standardization 
and conirmation.
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Early diagnosis and accurate prognosis of organ-conined 
PCa coupled with identiication of predictive markers that 
can be identiied to guide treatment options is still the 
goal that the PCa research community is striving towards. 
The discovery of novel noninvasive markers would aid in 
this effort tremendously by reducing biopsy procedures, 
surgeries and treatments for men who would not see a beneit. 
Currently, no single test can achieve the above goals and we 
predict that one single biomarker will not be able to fulill 
the above requirements for the next PCa screening tool. 
Due to the heterogeneity of the disease, no one biomarker 
will be diagnostic and prognostic for every patient. On this 
basis, we summarize that the next biomarkers for PCa will 
most likely be an assay employing multiple biomarkers 
assayed in combination using protein and gene microarrays, 
containing markers that are differentially expressed in PCa.
The emergence of the ‘omics’ era has created great insight 
into the mechanisms and networks involved in disease 
progression and etiology. Speciically, proteomics has 
provided information on the post-translational fate of 
genes, through the analysis of protein expression levels 
and post-translational modiications. A challenge with 
proteomic analysis of biological luids such as plasma and 
serum is the large dynamic range of protein concentrations.
(171) Increasing improvements in genomic technologies 
facilitated the migration from array-based methods to ‘next-
generation’ sequencing platforms. Metabolomic analysis of 
PCa tissues and urine identiied that sarcosine tissue levels 
correlate with PCa progression and metastasis.(172)
Proteomic, Genomic and Metabolomic 
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